PTGX
Closed
Protagonist Therapeutics Inc
50.21
-5.06 (-9.16%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 55.27
Day's Range: 49.92 - 55.675
Send
sign up or login to leave a comment!
When Written:
18.45
Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based drugs to address unmet medical needs. The company's lead product candidate, PTG-300, is a novel injectable hepcidin mimetic that is being developed for the treatment of iron overload disorders such as beta-thalassemia and hereditary hemochromatosis.
Protagonist Therapeutics also has a pipeline of other peptide-based drug candidates in various stages of development, including PTG-200, which is being developed for the treatment of inflammatory bowel disease, and PTG-100, which is being developed for the treatment of gastrointestinal disorders.
The company was founded in 2003 and is headquartered in Newark, California. Protagonist Therapeutics is publicly traded on the NASDAQ under the ticker symbol PTGX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Protagonist Therapeutics also has a pipeline of other peptide-based drug candidates in various stages of development, including PTG-200, which is being developed for the treatment of inflammatory bowel disease, and PTG-100, which is being developed for the treatment of gastrointestinal disorders.
The company was founded in 2003 and is headquartered in Newark, California. Protagonist Therapeutics is publicly traded on the NASDAQ under the ticker symbol PTGX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!